S&K Therapeutics is a biotechnology company developing innovative immunomodulatory medicines. Our AI-driven discovery platform and molecular docking simulations speed the identification and optimization of novel candidates. We focus on autoimmune and inflammatory diseases with a pipeline spanning small-molecule NLRP3 inhibitors, immunostimulatory aptamers, and growth factor?mimetic peptides. Robust translational systems combine biomarker strategies, preclinical validation, and scalable CMC to advance programs efficiently into clinical trials. We are building GMP-compliant quality frameworks and global regulatory pathways to enable commercialization. Our goal is to deliver precision medicines that improve outcomes and create lasting value for patients, clinicians, and partners worldwide.

S&K Therapeutics develops precision medicines for autoimmune and inflammatory diseases. Our pipeline includes NLRP3 inhibitors, immunostimulatory aptamers, and growth factor?mimetic peptides, supported by AI-driven discovery to accelerate innovation and clinical progress.